Missouri Orders Eli Lilly to End 340B Claims-Data Requirement
The attorney general says the company’s demand for detailed patient claims data harms safety‑net hospitals with possible enforcement under the Missouri Merchandising Practices Act.
Overview
- Missouri Attorney General Catherine Hanaway issued a cease‑and‑desist on Oct. 26 ordering Eli Lilly to stop conditioning 340B drug discounts on hospitals’ submission of detailed claims data and to stop using data already collected in the state.
- The letter accuses Lilly of misleading purchasers by advertising federally required 340B prices while denying those discounts to hospitals that refuse to provide the demanded data and warns of enforcement under state consumer‑protection law.
- Lilly expanded the data requirement earlier in 2026 and cut University of Missouri Health Care off from 340B pricing on July 2 after the system declined to comply, leading MU Health Care to temporarily supply data while reserving legal rights.
- Hospitals and trade groups have asked federal regulators to intervene and multiple hospitals, including Tampa General and Dartmouth‑Hitchcock and several in Massachusetts, have filed federal suits that remain pending.
- Supporters of the hospitals say the policy threatens rural and safety‑net services that rely on 340B savings for clinics, emergency care and cancer treatment, while Lilly says the data are needed to detect fraud and duplicate discounts tied to the Inflation Reduction Act.